Cytochrome P450 2C19, 2C9, and 3A4 (CYP2C19/CYP2C9/CYP3A4)

The Cytochrome P450 (CYP) enzymes, specifically the CYP2C19, CYP2C9, and CYP3A4 isoforms, are critical heme-containing monooxygenases located primarily in the endoplasmic reticulum of hepatocytes (UniProt P33261, P11712, P08684). They play a central role in the phase I metabolism of approximately 70-80% of clinically used drugs, as well as the synthesis and degradation of endogenous compounds like steroids and fatty acids (NIH/PMC 16141567). While these enzymes are not the primary therapeutic targets for antifungal therapy, they are significant 'off-targets' or metabolic targets for drugs like fluconazole. Fluconazole acts as a potent inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4, which can lead to profound drug-drug interactions by elevating the plasma concentrations of co-administered medications (StatPearls, 2024). For example, inhibition of CYP2C19 can reduce the activation of the prodrug clopidogrel, while inhibition of CYP2C9 can dangerously increase warfarin levels (FDA, 2023). Understanding the activity and genetic polymorphisms of these enzymes is essential for predicting adverse drug reactions and optimizing therapeutic dosing in clinical practice.

Other names

Cytochrome P450 family 2 subfamily C member 19Cytochrome P450 family 2 subfamily C member 9Cytochrome P450 family 3 subfamily A member 4CYP450Microsomal monooxygenasesHeme-thiolate monooxygenases

Fluconazole acts as a competitive inhibitor of these human Cytochrome P450 enzymes by binding to the heme iron atom within the active site, thereby preventing the oxidative metabolism of co-administered substrate drugs (StatPearls, 2024; PubChem CID 3365).